about
The role of genetic variation near interferon-kappa in systemic lupus erythematosusA large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosusVariable association of reactive intermediate genes with systemic lupus erythematosus in populations with different African ancestryMolecular analysis of major histocompatibility complex alleles associated with the lupus anticoagulantNovel sequence feature variant type analysis of the HLA genetic association in systemic sclerosisAssociation scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variantsANKH variants associated with ankylosing spondylitis: gender differencesNovel genetic markers in the 5'-flanking region of ANKH are associated with ankylosing spondylitisSystemic sclerosis (scleroderma): specific autoantigen genes are selectively overexpressed in scleroderma fibroblastsIRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosusA functional haplotype of UBE2L3 confers risk for systemic lupus erythematosusAdmixture mapping in lupus identifies multiple functional variants within IFIH1 associated with apoptosis, inflammation, and autoantibody productionPredictors of fatigue severity in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohortTime to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohortInteraction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility.Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related lociNew population-based reference values for spinal mobility measures based on the 2009-2010 National Health and Nutrition Examination Survey.Effects of statins on proinflammatory/prothrombotic biomarkers and on disease activity scores in SLE patients: data from LUMINA (LXXVI), a multi-ethnic US cohort.American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.High-throughput single-nucleotide polymorphism analysis of the IL1RN locus in patients with ankylosing spondylitis by matrix-assisted laser desorption ionization-time-of-flight mass spectrometry.Relationship between adherence to study and clinic visits in systemic lupus erythematosus patients: data from the LUMINA cohort.Predictors of post-partum damage accrual in systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (XXXVIII).Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)The impact of increased body mass index on systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA XLVI) [corrected].Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV).Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations.Systemic lupus erythematosus in a multiethnic US cohort: XLIII. The significance of thrombocytopenia as a prognostic factor.Features associated with, and the impact of, hemolytic anemia in patients with systemic lupus erythematosus: LX, results from a multiethnic cohort.Evaluation of TRAF6 in a large multiancestral lupus cohortPrognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death.Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort.Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort.Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort.Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests.Peripheral vascular damage in systemic lupus erythematosus: data from LUMINA, a large multi-ethnic U.S. cohort (LXIX)Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort.Human leucocyte antigen typing in rheumatoid arthritis/polymyositis overlap syndrome.US patients of Hispanic and African ancestry develop lupus nephritis early in the disease course: data from LUMINA, a multiethnic US cohort (LUMINA LXXIV).Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): LXI. Value of C-reactive protein as a marker of disease activity and damage.Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII)
P50
Q21296846-448A39B3-CEA4-4A0E-9822-4EE82A4723A3Q24629130-A54A5C32-5005-4CA6-A8CC-5EFD13B6C6C1Q24633276-CFE991C6-365F-46F0-A9BC-3250EDD02C72Q24633473-C3051318-D401-448D-8341-AC9E6C97455DQ24645988-C6AADB3A-164A-4717-9D4F-C92007F79267Q24646663-E9C9BC62-FF37-429B-BEEE-E98E3701442EQ24816663-25DAD855-D657-48BC-AE77-4B36A7BBFBB2Q28182601-3D82D01B-0C9A-47D7-B251-EDB8E63CD436Q28210021-C0E79910-584C-4B66-A8C1-9DFD16E0483EQ28253129-4B1FFEB5-A48B-4934-9F0F-507FA11DB26BQ28263690-FA9107CA-F2DB-46B4-9FF2-064E2E1C48C0Q28486228-123AFB8F-7490-4E3A-A1D2-BD05F7ABEB5AQ28743863-0DE414CB-F3A7-48F9-B229-94E6E4F39352Q28766942-14D1327A-856D-4D3D-A227-E56BD49C2C26Q29417082-3F2E9028-7373-490F-B83C-B4A58F60FF0CQ30417517-0798F4A1-4752-4104-8376-72722FAFB5C3Q30586397-432BC863-59CE-41CF-B729-1B071827A63EQ30746151-CF957586-4256-46F0-AD17-E796B1C787D9Q30829836-B6D7DEEA-583F-48B2-BDA7-668754043685Q30959623-C675C805-6A9A-4169-8B7D-F1A8D8613810Q30967796-5289DB7E-34B2-44C2-9923-AF625B3A8797Q31050711-6CA2E4D6-4E82-4C66-9E5A-488D6B8A01BFQ31107094-8DC8537C-5D76-4743-B563-0A5F429E871CQ31114844-74774682-D7A1-4F5F-90A0-2229CCDEB998Q31129756-479D8DFD-866A-4B4B-A26D-8A4DB72240A4Q33357666-C2C52D8A-091F-4F49-9E3E-09EF0F650DC2Q33374070-D74F469A-9CF3-4AE9-8B15-7FDD1BE45784Q33380972-95F60434-C480-41B8-B94E-DEBAC2179CDDQ33399089-3791EB08-6790-4EBC-A7A5-62E7DBC9737AQ33403579-86215F67-4095-4330-809F-C6A04C6F8DC5Q33411232-766F00BE-3FE0-4E13-90A2-567CD3D3830EQ33448450-2A2AB416-F09D-4A23-A581-56555ECCC29EQ33455990-117DDE14-A73E-4E42-ABAC-F6A82E01922EQ33502230-DDA81282-F9B9-4D5D-8BF4-44E069A95739Q33511924-36CB6723-EDD1-4C44-8BA6-EDB1BFFB9F76Q33555419-1055C67B-F6DB-4FBB-9791-C7985B2D1960Q33578374-C5F55059-5EA8-49EF-B830-D2275460D11CQ33632025-2846E76B-D5DD-44EF-9138-1669DADDDC19Q33635868-A7DDFB13-8A1A-448C-BEB2-DC6A08CE9E3AQ33635924-8D8BEFB4-176A-4D4A-A573-44FCA4B7326A
P50
description
forsker
@nb
researcher
@en
name
John D Reveille
@en
John D Reveille
@nb
John D Reveille
@nl
Reveille JD
@ast
Reveille JD
@es
type
label
John D Reveille
@en
John D Reveille
@nb
John D Reveille
@nl
Reveille JD
@ast
Reveille JD
@es
altLabel
Reveille JD
@en
prefLabel
John D Reveille
@en
John D Reveille
@nb
John D Reveille
@nl
Reveille JD
@ast
Reveille JD
@es